References
- Steiß J O, Strohner P, Zimmer K P, Lindemann H. Reduction of the total IgE level by omalizumab in children and adolescents. J Asthma 2008; 45: 233–236
- Adelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L, Zetterstrom O, Byrne A, Champain K, Thirlwell J, Cioppa G D, Sandström T. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106: 253–259
- Busse W, Corren J, Lanier B Q, McAlary M, Fowler-Taylor A, Cioppa G D, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108: 184–190
- Casale T B, Bernstein I L, Busse W W, LaForce C F, Tinkelman D G, Stoltz R R, Dockhorn R J, Reimann J, Su J Q, Fick R B, Jr, Adelman D C. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997; 100: 110–121
- Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor A F, Rohane P. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001; 108: E36
- Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thrilwell J, Gupta N, Della Cioppa G. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18: 254–261
- Slavin R, Ferioli C, Tannenbaum S, Martin C, Blogg M, Lowe P. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing immunoglobulin-E and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol 2008, In press